Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;17(1):633-638.
doi: 10.3892/etm.2018.7031. Epub 2018 Nov 29.

Acquired hemophilia A presenting as progressive intra-abdominal hemorrhage, muscle hemorrhage and hemothorax postpartum: A case report and literature review

Affiliations

Acquired hemophilia A presenting as progressive intra-abdominal hemorrhage, muscle hemorrhage and hemothorax postpartum: A case report and literature review

Liying Xu et al. Exp Ther Med. 2019 Jan.

Abstract

Acquired hemophilia A (AHA) is a rare antibody-mediated condition in which autoantibodies form against a coagulation factor, most commonly factor VIII (FVIII), causing severe coagulopathy. Here the present report presents a case of AHA in a 35-year-old postpartum woman with continuous polyserous bloody effusions who was admitted to the First Affiliated Hospital of Zhejiang Chinese Medical University (Hangzhou, China) in October 2017 without a history of trauma, anticoagulation treatment or coagulopathy. At presentation, the patient's hemoglobin level was low (70 g/l; normal range: 115-150 g/l) g/l, blood pressure was 89/58 mmHg (normal range, 90-140/60-90 mmHg), and activated partial thromboplastin time was 68.4 sec (normal range: 25.0-36.0 sec), with a normal international normalized ratio (0.94; normal range, 0.8-1.2). The reaction time in thrombography was prolonged (35.8 min; normal range: 5-10 min), coagulation FVIII had markedly decreased activity (12.6%; normal range, 60-150%), and FVIII inhibitor had a high titer [7.4 Bethesda units (BU)/ml; normal range, 0-0.6 BU/ml]. Notably, the patient's autoantibody level was markedly higher than normal (1:320; normal range: <1:100). The patient was successfully treated with bleeding control, eradication of FVIII inhibitor, and treatment of the underlying disease. To the best of our knowledge, this is the first case of AHA with polyserous bloody effusions in a patient with an autoimmune disorder during the postpartum period. Reports of such rare cases will aid the characterization of disease pathogenesis, which may in turn lead to the recognition and timely treatment of this rare disorder.

Keywords: China; acquired hemophilia A; hemorrhage; polyserous effusions; premature delivery.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Contrast-enhancement computed tomography scan showing (A and B) pleural effusion, (C) right abdominal cavity effusion and (D) pelvic effusion and exudative lesions of the soft tissues surrounding the right groin and thigh.
Figure 2.
Figure 2.
(A) Color doppler ultrasonography showing mild mitral valve reflux. (B) Tissue doppler imaging showing tricuspid valve regurgitation, high pulmonary artery systolic blood pressure and reduced diastolic left ventricular function. The parameters of cardiac function were as follows: Right ventricular internal dimension in diastole, 26.1 mm; intraventricular septum in diastole, 7.6 mm; left ventricular internal dimension-in diastole, 43.1 mm; left ventricular posterior wall dimension, 7.6 mm; left ventricular internal dimension in systole, 23.4 mm; heart rate, 84 bpm; aorta, 23.1 mm; left atrium, 32.5 mm; fractional shortening, 45.7%; ejection fraction, 77.4%).
Figure 3.
Figure 3.
Thromboelastography showing a prolonged R-time (35.8 min) and K-time (15.3 min), a narrowed angle (35.2°), decreased MA (44.5 mm), decreased CI (−28.8) and normal clot lysis, which is reported in terms of EPL (0.0%) and LY30% (0.0%). R, reaction time; K, coagulation time; deg, degree; MA, maximum amplitude; CI, coagulation index; EPL, estimated percent lysis; LY30%, percent clot lysis at 30 min after maximum amplitude; A, amplitude.
Figure 4.
Figure 4.
Schematic flowchart for the diagnosis of acquired hemophilia, lupus anticoagulant and single factor deficiency. FVIII, factor VIII; aPTT, activated partial thromboplastin time.

Similar articles

Cited by

References

    1. Vautier M, de Boysson H, Creveuil C, Repesse Y, Borel-Derlon A, Troussard X, Damaj GL, Bienvenu B, Gautier P, Aouba A. Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia. Medicine (Baltimore) 2016;95:e5232. doi: 10.1097/MD.0000000000005232. - DOI - PMC - PubMed
    1. Sakurai Y, Takeda T. Acquired hemophilia A: A frequently overlooked autoimmune hemorrhagic disorder. J Immunol Res. 2014;2014:320674. doi: 10.1155/2014/320674. - DOI - PMC - PubMed
    1. Collins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Castellano MEM, Shima M, St-Louis J, Lévesque H. Research article Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Research Notes Notes Research Notes. 2010;3(161) - PMC - PubMed
    1. Aljasser MI, Sladden C, Crawford RI, Au S. Bullous pemphigoid associated with acquired hemophilia A: A rare association of autoimmune disease. J Cutan Med Surg. 2014;18:123–126. doi: 10.2310/7750.2013.13060. - DOI - PubMed
    1. Olteanu M, Niţu M, Golli A. Tuberculosis mesenteric adenopathy and polyserositis. Rom J Morphol Embryol. 2012;53:835–840. - PubMed